Clot-specific streptokinase proteins possessing altered...

Details Clot-specific streptokinase proteins possessing altered... Clot-specific streptokinase proteins possessing altered...

2007-01-16

2007-01-16

Swope, Sheridan (Department: 1656)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Hydrolase

C435S069100, C435S069600, C435S069700, C435S070100, C435S071100

Reexamination Certificate

active

09940235

ABSTRACT:
The invention disclosed herein provides clot specific streptokinase proteins possessing altered plasminogen characteristics, including enhanced fibrin selectivity. The kinetics of plasminogen activation by these proteins are distinct from those of natural streptokinase, in that there is a temporary delay or lag in the initial rate of catalytic conversion of plasminogen to plasmin. Also disclosed are processes for preparing the proteins.

REFERENCES:
patent: 5026772 (1991-06-01), Kobayashi et al.
patent: 5151412 (1992-09-01), Brown
patent: 5187098 (1993-02-01), Malke et al.
patent: 5434073 (1995-07-01), Dawson et al.
patent: 5772996 (1998-06-01), Atkinson
patent: 6054312 (2000-04-01), Larocca et al.
patent: 0 397 366 (1990-11-01), None
patent: WO 91/17765 (1991-11-01), None
Wishart et al, A single mutation converts a novel phosphotyrosine binding domain into a dual-specificity phosphatase.J Biol Chem. Nov. 10, 1995;270(45):26782-5.
Witkowski et al, Conversion of a beta-ketoacyl synthase to a malonyl decarboxylase by replacement of the active-site cysteine with glutamine. Biochemistry. Sep. 7, 1999;38(36):11643-50.
Goldstein et al A chimeric streptokinase with unexpected fibrinolytic selectivity. Thromb Haemost. Sep. 1996;76(3):429-38.
EMBL database ID No. HSFIBI Jul. 16, 1988 Gronostajski et al.
U.S. Appl. No. 10/631,588 Sahni et al, filed Jul. 31, 2003. STIC in house alignment of SEQ ID No.: 2 and SEQ ID No.: 11.
Kornblihtt et al., Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene. EMBO J. Jul. 1985;4(7):1755-9.
Banerjee et al, Streptokinase—a clinically useful thrombolytic agent.Biotechnol Adv. Feb. 2004:22(4):287-307. Review.
Jackson et al, Active streptokinase from the cloned gene inStreptococcus sanguisis without the carboxy-terminal 32 residues.Biochemistry. Jan. 14, 1986;25(1):108-14.
Johnson et al, Influence of primary sequence transpositions on the folding pathways of ribonuclease T1.Biochemistry. Aug. 6, 1996;35(31):10223-33.
Galye et al, Identification of regions in interleukin-1 alpha important for activity.□□J Biol Chem. Oct. 15, 1993;268(29):22105-11.
Whisstock et al, Prediction of protein function from protein seqeunce and structure.□□Q Rev Biophys. Aug. 2003;36(3):307-40. Review.
Lucas et al., The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem. Apr. 10, 1983;258(7):4249-56.
Williams et al., Solution structure of a pair of fibronectin type 1 modules with fibrin binding activity. J Mol Biol. Jan. 28, 1994;235(4):1302-11.
Huston et al., Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli.Proc Natl Acad Sci U S A. Aug. 1988;85(16):5879-83.
Castellino, “Recent Advances in the Chemistry of the Fibrinolytic System”,Chemical Reviews;vol. 81, No. 5; pp. 431-446 (1981).
Fay et al., “Functional Analysis of the Amino- and Carboxyl-Termini of Streptokinase”,Thromb Haemost;vol. 79, No. 5; pp. 985-991 (1998).
Fears, “Binding of plasminogen activators to fibrin: characterization and pharmacological consequences”,Biochem. J.;vol. 261, No. 2; pp. 313-324 (1989).
Hagenson et al., “Expression of streptokinase inPichia pastorisyeast”,Enzyme Microb. Technol.;vol. 11, No. 10; pp. 650-656 (1989).
Jackson et al., “Complete Amino Acid Sequence of streptokinase and Its Homology with Serine Proteases”,Biochemistry;vol. 21, No. 25; pp. 6620-6625 (1982).
Kim et al., “C-Terminal Peptide Of Streptokinase, Met369-Pro373, Is Important In Plasminogen Activation”,Biochemistry and Molecular Biology International;vol. 40, No. 5; pp. 939-945 (1996).
Lee et al., “Identification Of The Functional Importance Of Valine-19 Residue In Streptokinase By N-Terminal Deletion And Site-Directed Mutagenesis”,Biochemistry and Molecular Biology International;vol. 41, No. 1; pp. 199-207; (1997).
Lin et al., “Mutation of Lysines in a Plasminogen Binding Region of Streptokinase Identifies Residues Important for Generating a Functional Activator Complex”,Biochemistry;vol. 35, No. 51; pp. 16879-16885 (1996).
Malke et al., “Expression of a streptokinase gene fromStreptococcus equisimilisinStreptococcus sanguis”, Molecular&General Genetics;vol. 196, No. 1; pp. 360-363 (1984).
Matsuka et al., “The NH2-terminal Fibrin-binding Site of Fibronectin Is Formed by Interacting Fourth and Fifth Finger Domains”,The Journal of Biological Chemistry;vol. 269, No. 13; pp. 9539-9546 (1994).
Malke et al., “Streptokinase: Cloning, expression, and excretion byEscherichia coli”, Proc. Natl. Acad. Sci USA;vol. 81, No. 10; pp. 3557-3561 (1984).
Nihalani et al., “Mapping of the plasminogen binding site of streptokinase with short synthetic peptides”,Protein Science;vol. 6, No. 6; pp. 1284-1292 (1997).
Rostagno et al., “Further Characterization of the NH2-terminal Fibrin-binding Site of Fibronectin”,The Journal of Biological Chemistry;vol. 269, No. 50; pp. 31938-31945 (1994).
Ruoslahti, “Fibronectin and Its Receptors”,Ann. Rev. Biochem.;vol. 57; pp. 375-413 (1988).
Smith et al., “Fibrinolysis with acyl-ezymes: a new approach to thrombolytic therapy”,Nature; vol. 290, No. 9; pp. 505-508 (1981).
Verheijen et al., “Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin”,The EMBO Journal;vol. 5, No. 13; pp. 3525-3530 (1986).
Wong et al., “Engineering and Production of Streptokinase in aBacillus subtilisExpression-Secretion System”,Applied and Environmental Microbiology;vol. 60, No. 2; pp. 517-523 (1994).
Pilar Alcala, et al., “Engineering ofEscherichia coliβ-galactosidase for solvent display of a Functional scFV Antibody Fragment,”Federation of Europeam Biochemical Societies,pp. 115-118 (2002).
Sven-Olof Enfors, “Control of in vivo Proteolysis in the Production of Recombinant Proteins,”TibTech,vol. 10: pp. 310-315 (1992).
CF Ford, et al., Fusion Tails for the Recovery and Purification of Recombinar Proteins,Protein Expr Purification,pp. 95-107 (1991).
Richard J. Jenny, et al., “A Critical Review of the Methods for Cleavage of Fusion Proteins with Thrombin and Factor Xa,”Protein Expression and Purification,vol.: 31 pp. 1-11(2003).
Shannon A. Marshall, et al. “Rational Design and Engineering of Therapeutic Proteins,”Drug Discovery Today,vol. 8, No. 5 pp. 212-221 (2003).
Didier Picard, “Regulation of Protein Function Through Expression of Chimaeric Proteins,”Current Opinion in Biotechnology,vol.: 5 p. 511-515 (1994).
Jackson, Kenneth W., et al., “Streptokinase and Staphylokinase,” Academic Press vol.; 80 pp. 387-394 (1981).
Kim, Dong Min, et al. “Asp41-His48 Region of Streptokinase Is Important in Binding to a Substrate Plasminogen,”Thrombosis Researchvol. 99 pp. 93-98 (2000).
Lee, Byeong Ryong, et al., “Site-Specific Alteration of GLY-24 in Streptokinase: Its Effect on Plasminogen Activation,”Biochemical and Biophysical Research Communicationsvol. 165, No. 3 pp. 1085-1090 (1989).
Malke, Horst, “Polymorphism of the Streptokinase Gene: Implications for the Pathogenesis of Post-Streptococcal Glomerulonephritis,”Gustav Fischer Verlagvol. 278 pp. 246-257 (1993).
Nihalani, Deepak, et al., “Streptokinase Contains Two Independent Plasminogen-Binding Sites,”Academic Press, Inc.vol. 217 pp. 1245-1254 (1995).
Potts, Jennifer R., et al., “Solution Structure of the N-Terminal F1 Module Pair from Human Fibronection,”Biochemistryvol. 38 pp. 8304-8312 (1999).
Reed, Guy L., et al., “Identification of a Plasminogen Binding Region in Streptokinase That Is Necessary for the Creation of a Functional Streptokinase-Plasminogen Activator Complex,”Biochemistryvol.

Affiliated with

Also associated with

Rating

Clot-specific streptokinase proteins possessing altered... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Clot-specific streptokinase proteins possessing altered..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Clot-specific streptokinase proteins possessing altered... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3787385